Exact Mass: 361.28145680200004

Exact Mass Matches: 361.28145680200004

Found 126 metabolites which its exact mass value is equals to given mass value 361.28145680200004, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

PHA-793887

N-(6,6-dimethyl-5-(1-methylpiperidine-4-carbonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-3-methylbutanamide

C19H31N5O2 (361.2477626)


   

N-Arachidonoylglycine

N-[(5Z,8Z,11Z,14Z)-1-oxo-5,8,11,14-Eicosatetraen-1-yl]glycine

C22H35NO3 (361.26168000000007)


N-Arachidonoylglycine (NAGly) is an endogenous lipid, which is a metabolite of the endocannabinoid anandamide by oxidation and acts as an efficacious agonist at GPR18. A previous study demonstrates that NAGly triggers antinociceptive and anti-inflammatory activities. A human metabolite taken as a putative food compound of mammalian origin [HMDB]

   

N-Arachidonoyl Glycine

(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-{4-[(1-hydroxyethylidene)amino]-2-methoxyphenoxy}oxane-2-carboxylic acid

C22H35NO3 (361.26168000000007)


N-arachidonoyl glycine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Arachidonic acid amide of Glycine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Arachidonoyl Glycine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Arachidonoyl Glycine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules. A human metabolite taken as a putative food compound of mammalian origin [HMDB]

   

(+)-Butaclamol

3-Tert-butyl-2,3,4,4a,8,9,13b,14-octahydro-1h-benzo[6,7]cyclohepta[1,2,3-de]pyrido[2,1-a]isoquinolin-3-ol

C25H31NO (361.2405516)


D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants

   

N-(1-Hydroxypropan-2-yl)icosa-5,8,11,14-tetraenamide

N-(1-Hydroxypropan-2-yl)icosa-5,8,11,14-tetraenamide

C23H39NO2 (361.2980634)


   

6-(6-(3r-Hydroxy-1e,5z-undecadien-1-yl)-2-pyridinyl)-1,5s-hexanediol

6-(6-(3r-Hydroxy-1e,5z-undecadien-1-yl)-2-pyridinyl)-1,5s-hexanediol

C22H35NO3 (361.26168000000007)


   

Cetaben

Benzoic acid, 4-(hexadecylamino)-, monosodium salt

C23H39NO2 (361.2980634)


C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent

   

Leucylnegamycin

(S)-L-threo-Hexonic acid

C15H31N5O5 (361.2325076)


   
   
   
   
   
   
   
   

Cetaben

4-(hexadecylamino)-benzoic acid

C23H39NO2 (361.2980634)


C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent

   

(Z)-N-<2-(4-hydroxy-3-methoxyphenyl)ethyl>-3-methyldodec-2-enamide|(Z)-N-[2-(4-hydroxy-3-methoxyphenyl)ethyl]-3-methyldodec-2-enamide|3-Methoxy-(Z)-N-[2-(4-Hydroxyphenyl)-ethyl]-3-methyl-2-dodecenamide

(Z)-N-<2-(4-hydroxy-3-methoxyphenyl)ethyl>-3-methyldodec-2-enamide|(Z)-N-[2-(4-hydroxy-3-methoxyphenyl)ethyl]-3-methyldodec-2-enamide|3-Methoxy-(Z)-N-[2-(4-Hydroxyphenyl)-ethyl]-3-methyl-2-dodecenamide

C22H35NO3 (361.26168000000007)


   
   

Methyl-homodaphniphyllat

Methyl-homodaphniphyllat

C23H39NO2 (361.2980634)


   

(Z)-N-<2-(3-hydroxy-4-methoxyphenyl)ethyl>-3-methyldodec-2-enamide|(Z)-N-[2-(3-hydroxy-4-methoxyphenyl)ethyl]-3-methyldodec-2-enamide|Me ether,3-hydroxy-(Z)-N-[2-(4-Hydroxyphenyl)-ethyl]-3-methyl-2-dodecenamide

(Z)-N-<2-(3-hydroxy-4-methoxyphenyl)ethyl>-3-methyldodec-2-enamide|(Z)-N-[2-(3-hydroxy-4-methoxyphenyl)ethyl]-3-methyldodec-2-enamide|Me ether,3-hydroxy-(Z)-N-[2-(4-Hydroxyphenyl)-ethyl]-3-methyl-2-dodecenamide

C22H35NO3 (361.26168000000007)


   

Delta16-20alpha- dimethylamino-3beta,4alpha-diol-5alpha-pregnane

Delta16-20alpha- dimethylamino-3beta,4alpha-diol-5alpha-pregnane

C23H39NO2 (361.2980634)


   
   

3beta-(dimethylamino)-pregn-16-one-20-ol|terminamine J

3beta-(dimethylamino)-pregn-16-one-20-ol|terminamine J

C23H39NO2 (361.2980634)


   
   
   
   

n-(1-hydroxy-1-phenylpropan-2-yl)tetradecanamide

n-(1-hydroxy-1-phenylpropan-2-yl)tetradecanamide

C23H39NO2 (361.2980634)


   
   
   

NAGly

N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-glycine

C22H35NO3 (361.26168000000007)


   

N-(3-hydroxy-propyl)arachidonoylamide

N-(3-hydroxy-propyl)-5Z,8Z,11Z,14Z-eicosatetraenoyl amine

C23H39NO2 (361.2980634)


   

N-(2-methoxy-ethyl)arachidonoylamide

N-(2-methoxy-ethyl)-5Z,8Z,11Z,14Z-eicosatetraenoyl amine

C23H39NO2 (361.2980634)


   

N-methyl N-(2-hydroxy-ethyl)arachidonoylamide

N-methyl-N-(2-hydroxy-ethyl)-5Z,8Z,11Z,14Z-eicosatetraenoyl amine

C23H39NO2 (361.2980634)


   

R-1 Methanandamide

N-(1R-methyl-2-hydroxy-ethyl)-5Z,8Z,11Z,14Z-eicosatetraenoyl amine

C23H39NO2 (361.2980634)


   

S-2 Methanandamide

N-(2-hydroxy-2S-methyl-ethyl)-5Z,8Z,11Z,14Z-eicosatetraenoyl amine

C23H39NO2 (361.2980634)


   

alpha-methyl anandamide

N-(2-methy-5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine

C23H39NO2 (361.2980634)


   

N-(5Z,8Z,11Z,14Z-heneicosatetraenoyl)-ethanolamine

N-(5Z,8Z,11Z,14Z-heneicosatetraenoyl)-ethanolamine

C23H39NO2 (361.2980634)


   
   

U-75302

6-(6-(3r-Hydroxy-1e,5z-undecadien-1-yl)-2-pyridinyl)-1,5s-hexanediol

C22H35NO3 (361.26168000000007)


   

S-1 Methanandamide

N-(2-hydroxy-1S-methylethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide

C23H39NO2 (361.2980634)


   

R-2 Methanandamide

N-(2R-hydroxypropyl)-5Z,8Z,11Z,14Z-eicosatetraenamide

C23H39NO2 (361.2980634)


   

5,8,11,14-all-cis-heneicosatetraenoylethanolamine

N-(5Z,8Z,11Z,14Z-heneicosatetraenoyl)-ethanolamine

C23H39NO2 (361.2980634)


   
   

Type IV cyanolipid 18:1 ester

(1-cyano-2-methylprop-2-en-1-yl) 9Z-octadecenoate

C23H39NO2 (361.2980634)


   

Type IV cyanolipid 18:1(11Z) ester

(1-cyano-2-methylprop-2-en-1-yl) 11Z-octadecenoate

C23H39NO2 (361.2980634)


   

Type III cyanolipid 18:1(9Z) ester

9Z-Octadecenoic acid, 3-cyano-2-methyl-2-propen-1-yl ester

C23H39NO2 (361.2980634)


   

Type III cyanolipid 18:1(11Z) ester

11Z-Octadecenoic acid, 3-cyano-2-methyl-2-propen-1-yl ester

C23H39NO2 (361.2980634)


   

NA 22:5;O2

N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-glycine

C22H35NO3 (361.26168000000007)


   

NA 23:4;O

N-(2-hydroxy-2S-methyl-ethyl)-5Z,8Z,11Z,14Z-eicosatetraenoyl amine

C23H39NO2 (361.2980634)


   

NAE 21:4

N-(2-methy-5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine

C23H39NO2 (361.2980634)


   

EEQ-EA

N-(17(18)-epoxy-5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine

C22H35NO3 (361.26168000000007)


   
   

sodium (Z)-N-methyl-N-9-octadecenylaminoacetate

sodium (Z)-N-methyl-N-9-octadecenylaminoacetate

C21H40NNaO2 (361.29565800000006)


   

2-(2-Hexyldecyloxy)benzamide

2-(2-Hexyldecyloxy)benzamide

C23H39NO2 (361.2980634)


   

Butaclamol

(+)-BUTACLAMOL

C25H31NO (361.2405516)


D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants

   

2-amino-1,9-dihydro-9-methyl-6H-purin-6-one

2-amino-1,9-dihydro-9-methyl-6H-purin-6-one

C24H31N3 (361.2517846)


   

3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-propyl-

3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-propyl-

C22H32FNO2 (361.2416944)


   

3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-propyl-, (aR,4R)- (9CI)

3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-propyl-, (aR,4R)- (9CI)

C22H32FNO2 (361.2416944)


   

(+/-)-butaclamol hcl

(+/-)-butaclamol hcl

C25H31NO (361.2405516)


   

1-(Piperidin-1-yl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)propan-2-ol

1-(Piperidin-1-yl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)propan-2-ol

C20H32BNO4 (361.2424262)


   

2,3,4,5-Tetrahydro-2-isobutyl-8-methyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole

2,3,4,5-Tetrahydro-2-isobutyl-8-methyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole

C24H31N3 (361.2517846)


   

N,N-dimethyl-N-(2-sulfoethyl)-1-hexadecanaminium

N,N-dimethyl-N-(2-sulfoethyl)-1-hexadecanaminium

C20H43SO2N (361.30143380000004)


   

4-(Triethoxysilylpropoxy)-2,2,6,6-Tetramethylpiperidine

4-(Triethoxysilylpropoxy)-2,2,6,6-Tetramethylpiperidine

C18H39NO4Si (361.2648214)


   
   
   

Decyl 2-acetamido-2-deoxy-β-D-glucopyranoside

Decyl 2-acetamido-2-deoxy-β-D-glucopyranoside

C18H35NO6 (361.24642500000004)


   

2-[acetyl-[3-(diethylamino)propyl]amino]-N-(2,4,6-trimethylphenyl)propanamide

2-[acetyl-[3-(diethylamino)propyl]amino]-N-(2,4,6-trimethylphenyl)propanamide

C21H35N3O2 (361.272913)


   

Butaclamol free base

Butaclamol free base

C25H31NO (361.2405516)


D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist

   

D-erythro-MAPP

D-erythro-MAPP

C23H39NO2 (361.2980634)


D-erythro-MAPP (D-e-MAPP) is a ceramidase inhibitor, with an IC50 of 1-5 μM in vitro[1].

   

N-(1-adamantyl)-4-[oxo(2-oxolanyl)methyl]-1-piperazinecarboxamide

N-(1-adamantyl)-4-[oxo(2-oxolanyl)methyl]-1-piperazinecarboxamide

C20H31N3O3 (361.23652960000004)


   

L-Seryl-L-lysyl-L-lysine

L-Seryl-L-lysyl-L-lysine

C15H31N5O5 (361.2325076)


   
   

17-(4-Hydroxyphenyl)heptadecanoate

17-(4-Hydroxyphenyl)heptadecanoate

C23H37O3- (361.27425519999997)


   
   

(5Z,8Z,11Z,14Z)-N-(1-Methyl-2-hydroxyethyl)-5,8,11,14-icosatetrenamide

(5Z,8Z,11Z,14Z)-N-(1-Methyl-2-hydroxyethyl)-5,8,11,14-icosatetrenamide

C23H39NO2 (361.2980634)


   

(2S)-6-amino-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-hydroxypropanoyl]amino]hexanoic acid

(2S)-6-amino-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-hydroxypropanoyl]amino]hexanoic acid

C15H31N5O5 (361.2325076)


   

N-[(1R,2S)-1-hydroxy-1-phenylpropan-2-yl]tetradecanamide

N-[(1R,2S)-1-hydroxy-1-phenylpropan-2-yl]tetradecanamide

C23H39NO2 (361.2980634)


   

1-[1-(Phenylmethyl)-4-piperidinyl]-3-(2,4,4-trimethylpentan-2-yl)thiourea

1-[1-(Phenylmethyl)-4-piperidinyl]-3-(2,4,4-trimethylpentan-2-yl)thiourea

C21H35N3S (361.25515500000006)


   
   

(4Z,7Z,10Z,13Z,15E,17S)-17-hydroperoxydocosa-4,7,10,13,15-pentaenoate

(4Z,7Z,10Z,13Z,15E,17S)-17-hydroperoxydocosa-4,7,10,13,15-pentaenoate

C22H33O4- (361.23787180000005)


   

(7Z,10Z,13Z,15E,19Z)-17-hydroperoxydocosa-7,10,13,15,19-pentaenoate

(7Z,10Z,13Z,15E,19Z)-17-hydroperoxydocosa-7,10,13,15,19-pentaenoate

C22H33O4- (361.23787180000005)


   

(7Z,10Z,12E,16Z,19Z)-14-hydroperoxydocosa-7,10,12,16,19-pentaenoate

(7Z,10Z,12E,16Z,19Z)-14-hydroperoxydocosa-7,10,12,16,19-pentaenoate

C22H33O4- (361.23787180000005)


   

(4Z,7Z,10Z,12E,16Z)-14-hydroperoxydocosa-4,7,10,12,16-pentaenoate

(4Z,7Z,10Z,12E,16Z)-14-hydroperoxydocosa-4,7,10,12,16-pentaenoate

C22H33O4- (361.23787180000005)


   
   
   

(8E,10Z,14E,16Z,19Z)-7,13-dihydroxydocosa-8,10,14,16,19-pentaenoate

(8E,10Z,14E,16Z,19Z)-7,13-dihydroxydocosa-8,10,14,16,19-pentaenoate

C22H33O4- (361.23787180000005)


   

2-[[(5E,8E,11E,14E)-Icosa-5,8,11,14-tetraenoyl]amino]acetic acid

2-[[(5E,8E,11E,14E)-Icosa-5,8,11,14-tetraenoyl]amino]acetic acid

C22H35NO3 (361.26168000000007)


   

N-[[(2R,3S,4R)-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)-N-propan-2-ylacetamide

N-[[(2R,3S,4R)-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)-N-propan-2-ylacetamide

C20H31N3O3 (361.23652960000004)


   

N-[[(2S,3R,4S)-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)-N-propan-2-ylacetamide

N-[[(2S,3R,4S)-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)-N-propan-2-ylacetamide

C20H31N3O3 (361.23652960000004)


   

(7Z,9E,11E,14S,16Z,19Z)-13,14-dihydroxydocosa-7,9,11,16,19-pentaenoate

(7Z,9E,11E,14S,16Z,19Z)-13,14-dihydroxydocosa-7,9,11,16,19-pentaenoate

C22H33O4- (361.23787180000005)


   

(7Z,10Z,12E,14S,16Z,19Z)-14,21-dihydroxydocosa-7,10,12,16,19-pentaenoate

(7Z,10Z,12E,14S,16Z,19Z)-14,21-dihydroxydocosa-7,10,12,16,19-pentaenoate

C22H33O4- (361.23787180000005)


   

(7R,8E,10E,12Z,14S,16Z,19Z)-7,14-dihydroxydocosa-8,10,12,16,19-pentaenoate

(7R,8E,10E,12Z,14S,16Z,19Z)-7,14-dihydroxydocosa-8,10,12,16,19-pentaenoate

C22H33O4- (361.23787180000005)


   

7,17-dihydroxy-(8Z,15E,19Z)-docosa-8,10,13,15,19-pentaenoate

7,17-dihydroxy-(8Z,15E,19Z)-docosa-8,10,13,15,19-pentaenoate

C22H33O4- (361.23787180000005)


A docosanoid anion that is the conjugate base of 7,17-dihydroxy-(8Z,15E,19Z)-docosa-8,10,13,15,19-pentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(7Z,10R,11E,13E,15Z,17S,19Z)-10,17-dihydroxydocosa-7,11,13,15,19-pentaenoate

(7Z,10R,11E,13E,15Z,17S,19Z)-10,17-dihydroxydocosa-7,11,13,15,19-pentaenoate

C22H33O4- (361.23787180000005)


   

(7Z,10Z,12E,14E,17S,19Z)-16,17-dihydroxydocosa-7,10,12,14,19-pentaenoate

(7Z,10Z,12E,14E,17S,19Z)-16,17-dihydroxydocosa-7,10,12,14,19-pentaenoate

C22H33O4- (361.23787180000005)


   

(7Z,10Z,12E,14S,16Z,19Z)-14-hydroperoxydocosa-7,10,12,16,19-pentaenoate

(7Z,10Z,12E,14S,16Z,19Z)-14-hydroperoxydocosa-7,10,12,16,19-pentaenoate

C22H33O4- (361.23787180000005)


   

(7Z,10Z,13Z,15E,17S,19Z)-17-hydroperoxydocosa-7,10,13,15,19-pentaenoate

(7Z,10Z,13Z,15E,17S,19Z)-17-hydroperoxydocosa-7,10,13,15,19-pentaenoate

C22H33O4- (361.23787180000005)


   

1,3-Di-O-trimethylsilyl dodecasphinganine

1,3-Di-O-trimethylsilyl dodecasphinganine

C18H43NO2Si2 (361.2832178)


   

N-Arachidonylglycine

N-arachidonoylglycine

C22H35NO3 (361.26168000000007)


Biologically active derivative of anandamide

   

N-methyl N-(2-hydroxy-ethyl) arachidonoyl amine

N-methyl N-(2-hydroxy-ethyl) arachidonoyl amine

C23H39NO2 (361.2980634)


   

resolvin T4(1-)

resolvin T4(1-)

C22H33O4 (361.23787180000005)


A docosanoid anion that is the conjugate base of resolvin T4, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

14(S),21-dihydroxy-(7Z,10Z,12E,16Z,19Z)-docosapentaenoate

14(S),21-dihydroxy-(7Z,10Z,12E,16Z,19Z)-docosapentaenoate

C22H33O4 (361.23787180000005)


A docosanoid anion that is the conjugate base of 14(S),21-dihydroxy-(7Z,10Z,12E,16Z,19Z)-docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(7R,14S)-dihydroxy-(8E,10E,12Z,16Z,19Z)-docosapentaenoate

(7R,14S)-dihydroxy-(8E,10E,12Z,16Z,19Z)-docosapentaenoate

C22H33O4 (361.23787180000005)


A docosanoid anion that is the conjugate base of (7R,14S)-dihydroxy-(8E,10E,12Z,16Z,19Z)-docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(10R,17S)-dihydroxy-(7Z,11E,13E,15Z,19Z)-docosapentaenoate

(10R,17S)-dihydroxy-(7Z,11E,13E,15Z,19Z)-docosapentaenoate

C22H33O4 (361.23787180000005)


A docosanoid anion that is the conjugate base of (10R,17S)-dihydroxy-(7Z,11E,13E,15Z,19Z)-docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

16,17(S)-dihydroxy-(7Z,10Z,13E,14E,19Z)-docosapentaenoate

16,17(S)-dihydroxy-(7Z,10Z,13E,14E,19Z)-docosapentaenoate

C22H33O4 (361.23787180000005)


A docosanoid anion that is the conjugate base of 16,17(S)-dihydroxy-(7Z,10Z,13E,14E,19Z)-docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(7Z,10Z,12E,14S,16Z,19Z)-14-hydroperoxydocosapentaenoate

(7Z,10Z,12E,14S,16Z,19Z)-14-hydroperoxydocosapentaenoate

C22H33O4 (361.23787180000005)


A (7Z,10Z,12E,16Z,19Z)-14-hydroperoxydocosapentaenoate in which the chiral centre at position 14 has S-configuration.

   

(7Z,10Z,13Z,15E,17S,19Z)-17-hydroperoxydocosapentaenoate

(7Z,10Z,13Z,15E,17S,19Z)-17-hydroperoxydocosapentaenoate

C22H33O4 (361.23787180000005)


A (7Z,10Z,13Z,15E,19Z)-17-hydroperoxydocosapentaenoate in which the chiral centre at position 17 has S-configuration. An intermediate of specialised proresolving mediators.

   

13,14(S)-dihydroxy-(7Z,9E,11E,16Z,19Z)-docosapentaenoate

13,14(S)-dihydroxy-(7Z,9E,11E,16Z,19Z)-docosapentaenoate

C22H33O4 (361.23787180000005)


A docosanoid anion that is the conjugate base of 13,14(S)-dihydroxy-(7Z,9E,11E,16Z,19Z)-docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

2-amino-1,3,4,5-icosanetetrol

2-amino-1,3,4,5-icosanetetrol

C20H43NO4 (361.31919180000006)


A tetrol that is 2-aminoicosane with the four hydroxy substituents located at position 1, 3, 4 and 5.

   
   
   

NA-Histamine 17:1(9Z)

NA-Histamine 17:1(9Z)

C22H39N3O (361.3092964)


   
   
   
   

(13s)-13-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1,13-dihydroxytridecan-4-one

(13s)-13-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1,13-dihydroxytridecan-4-one

C18H35NO6 (361.24642500000004)


   

(1r,2r,4r,5r,6s,7r,8r,9r,10r,13r,16s,17r)-11-ethyl-6,13-dimethyl-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecane-4,7,16-triol

(1r,2r,4r,5r,6s,7r,8r,9r,10r,13r,16s,17r)-11-ethyl-6,13-dimethyl-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecane-4,7,16-triol

C22H35NO3 (361.26168000000007)


   

4-{6-hydroxy-14-isopropyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹²]hexadecan-2-yl}butanoic acid

4-{6-hydroxy-14-isopropyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹²]hexadecan-2-yl}butanoic acid

C22H35NO3 (361.26168000000007)


   

13-(2-hydroxyethyl)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecane-6,8-diol

13-(2-hydroxyethyl)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecane-6,8-diol

C22H35NO3 (361.26168000000007)


   

(1s,2r,3r,4s,5s,8s,9s,10r,13r,16r,17r)-11-ethyl-16-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8-diol

(1s,2r,3r,4s,5s,8s,9s,10r,13r,16r,17r)-11-ethyl-16-methoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8-diol

C22H35NO3 (361.26168000000007)


   

13-[3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1,13-dihydroxytridecan-4-one

13-[3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1,13-dihydroxytridecan-4-one

C18H35NO6 (361.24642500000004)


   

n-[3-(acetyloxy)octadeca-6,9,12,15-tetraen-2-yl]ethanimidic acid

n-[3-(acetyloxy)octadeca-6,9,12,15-tetraen-2-yl]ethanimidic acid

C22H35NO3 (361.26168000000007)